Next-generation Prostate-specific Antigen Test: Precursor Form of Prostate-specific Antigen

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2014 Aug 20

PMID 25135462

Citations 1

Authors

Kazuto Ito

Yuji Fujizuka

Kiyohide Ishikura

Bernard Cook

Affiliations

Soon will be listed here.

Abstract

An urgent need exists to develop a more sophisticated screening system in order to improve diagnostic accuracy of clinically significant cancer and also to reduce the drawbacks of prostate-specific antigen (PSA) screening including overdetection and overtreatment. The most promising next-generation PSA test, which can improve the management of prostate cancer, may be proenzyme PSA (proPSA) or precursor PSA (pPSA). proPSA has pro-leader peptide sequences of seven or less amino acids and previous studies demonstrated that [-2]proPSA, which contains only a 2-amino-acid propeptide leader, could be more useful not only to distinguish between men with and without cancer, but also between tumors with aggressive features with performance exceeding other classical PSA-related indices including ratio of free PSA to total PSA (%f-PSA) and PSA density. Recently, it was demonstrated that baseline [-2]proPSA-related indices were independent factors to predict pathological reclassification at one year or several years after entering active surveillance. Furthermore, a retrospective study suggested that [-2]proPSA might be a useful predictive marker for future developing clinically manifested prostate cancer as well as aggressive tumors. ProPSA-related indices may have the potential for developing a more ideal risk classification for men at risk for prostate cancer, with a screening system maintaining the sensitivity of detecting clinically significant prostate cancer while saving cost, individualized treatment strategies, and follow-up procedures of active surveillance or active treatments. At a minimum, proPSA will be one of the most important new markers on the prostate cancer management in the near future.

Citing Articles

Controversies in managing localized prostate cancer: introduction.

Arai Y Int J Clin Oncol. 2014; 19(5):780-1.

PMID: 25154509 DOI: 10.1007/s10147-014-0744-9.

References

Lughezzani G, Lazzeri M, Haese A, McNicholas T, De La Taille A, Buffi N . Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2013; 66(5):906-12. DOI: 10.1016/j.eururo.2013.12.005. View

Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G . Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One. 2013; 8(7):e67687. PMC: 3701535. DOI: 10.1371/journal.pone.0067687. View

Bangma C, Wildhagen M, Yurdakul G, Schroder F, Blijenberg B . The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int. 2004; 93(6):720-4. DOI: 10.1111/j.1464-410X.2003.04733.x. View

Fossati N, Lazzeri M, Larcher A . Re: Editorial Comment on Clinical Performance of Serum Isoform (-2)proPSA (p2PSA) and its Derivatives, Namely %p2PSA and PHI (Prostate Health Index) in Men Younger than 60 Years of Age: Results from a Multicentric European Study: S. S. Taneja J Urol.... J Urol. 2015; 194(1):265. DOI: 10.1016/j.juro.2014.12.103. View

Mikolajczyk S, Rittenhouse H . Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003; 52(2):86-91. DOI: 10.2302/kjm.52.86. View

Igawa T, Takehara K, Onita T, Ito K, Sakai H . Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions. J Clin Lab Anal. 2014; 28(4):315-9. PMC: 6807334. DOI: 10.1002/jcla.21687. View

Heidegger I, Klocker H, Steiner E, Skradski V, Ladurner M, Pichler R . [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2013; 17(1):70-4. DOI: 10.1038/pcan.2013.50. View

Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E . Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol. 2013; 190(2):496-501. DOI: 10.1016/j.juro.2013.02.3184. View

Stephan C, Kahrs A, Cammann H, Lein M, Schrader M, Deger S . A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate. 2008; 69(2):198-207. DOI: 10.1002/pros.20872. View

10.

Chan T, Mikolajczyk S, Lecksell K, Shue M, Rittenhouse H, Partin A . Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology. 2003; 62(1):177-81. DOI: 10.1016/s0090-4295(03)00138-9. View

11.

Perdona S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C . Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. 2012; 73(3):227-35. DOI: 10.1002/pros.22561. View

12.

Sokoll L, Wang Y, Feng Z, Kagan J, Partin A, Sanda M . [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008; 180(2):539-43. PMC: 2647141. DOI: 10.1016/j.juro.2008.04.015. View

13.

Mikolajczyk S, Millar L, Wang T, Rittenhouse H, Wolfert R, Marks L . "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000; 55(1):41-5. DOI: 10.1016/s0090-4295(99)00372-6. View

14.

Lazzeri M, Haese A, De La Taille A, Palou Redorta J, McNicholas T, Lughezzani G . Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol. 2013; 63(6):986-94. DOI: 10.1016/j.eururo.2013.01.011. View

15.

Mikolajczyk S, Marker K, Millar L, Kumar A, Saedi M, Payne J . A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001; 61(18):6958-63. View

16.

Ng C, Chiu P, Lam N, Lam H, Lee K, Hou S . The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol. 2013; 46(4):711-7. DOI: 10.1007/s11255-013-0582-0. View

17.

Kumar A, Mikolajczyk S, Goel A, Millar L, Saedi M . Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997; 57(15):3111-4. View

18.

Jansen F, van Schaik R, Kurstjens J, Horninger W, Klocker H, Bektic J . Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010; 57(6):921-7. DOI: 10.1016/j.eururo.2010.02.003. View

19.

Lazzeri M, Haese A, Abrate A, De La Taille A, Palou Redorta J, McNicholas T . Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the.... BJU Int. 2013; 112(3):313-21. DOI: 10.1111/bju.12217. View

20.

Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y . Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol. 2012; 31(2):305-11. DOI: 10.1007/s00345-012-0927-9. View